| Literature DB >> 36210854 |
Muhammad Haseeb Ur Rehman1, Uzma Saleem1, Bashir Ahmad2, Memoona Rashid3.
Abstract
Drugs obtained from medicinal plants have always played a pivotal role in the field of medicine and to identify novel compounds. Safety profiling of plant extracts is of utmost importance during the discovery of new biologically active compounds and the determination of their efficacy. It is imperative to conduct toxicity studies before exploring the pharmacological properties and perspectives of any plant. The present work aims to provide a detailed insight into the phytochemical and toxicological profiling of methanolic extract of Zephyranthes citrina (MEZ). Guidelines to perform subacute toxicity study (407) and acute toxicity study (425) provided by the organization of economic cooperation and development (OECD) were followed. A single orally administered dose of 2000 mg/kg to albino mice was used for acute oral toxicity testing. In the subacute toxicity study, MEZ in doses of 100, 200, and 400 mg/kg was administered orally, consecutive for 28 days. Results of each parameter were compared to the control group. In both studies, the weight of animals and their selected organs showed consistency with that of the control group. No major toxicity or organ damage was recorded except for some minor alterations in a few parameters such as in the acute study, leukocyte count was increased and decreased platelet count, while in the subacute study platelet count increased in all doses. In the acute toxicity profile liver enzymes Alanine aminotransferase (ALT), as well as, aspartate aminotransferase (AST) were found to be slightly raised while alkaline phosphatase (ALP) was decreased. In subacute toxicity profiling, AST and ALT were not affected by any dose while ALP was decreased only at doses of 200 and 400 mg/kg. Uric acid was raised at a dose of 100 mg/kg. In acute toxicity, at 2000 mg/kg, creatinine and uric acid increased while urea levels decreased. Therefore, it is concluded that the LD50 of MEZ is more than 2000 mg/kg and the toxicity profile of MEZ was generally found to be safe.Entities:
Keywords: LD50; UHPLC/MS; Zephyranthes citrina; phytochemical analysis; toxicological study
Year: 2022 PMID: 36210854 PMCID: PMC9539839 DOI: 10.3389/fphar.2022.1007310
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
Groups and doses of subacute toxicity study.
| Group | Dose |
|---|---|
| 1 | Control (5–10 ml/kg Normal Saline) |
| 2 | MEZ |
| 3 | MEZ 200 mg/kg of body weight |
| 4 | MEZ 400 mg/kg of body weight |
MEZ: Methanolic Extract of Z. citrina.
Total content of bioactive compounds and antioxidant activity of MEZ.
| Assay | Parameter | Results |
|---|---|---|
| Percent extract yield | 19.7% | |
| Content of bioactive compounds | Total flavonoid content | 37.92 ± 0.26 |
| Total phenolic content | 25.93 ± 0.19 | |
| Free radical scavenging activity | DPPH (%) | 88.23 ± 2.95 |
UHPLC-MS analysis of methanolic extract of Z. citrina.
| S. No. | RT | Base peak (m/z) | Molecular Mass | Proposed compound | Compound class | Molecular formula |
|---|---|---|---|---|---|---|
| 1 | 2.294 | 272.9595 | 273.9647 | Ribose-1-arsenate | Carbohydrate | C5 H11 As O8 |
| 2 | 2.474 | 241.0926 | 242.0998 | D-erythro-D-galacto-octitol | Alditol | C8 H18 O S |
| 3 | 2.485 | 173.1052 | 174.1125 | L-Arginine | Amino Acid | C6 H14 N4 O S |
| 4 | 2.501 | 224.0787 | 225.086 | Acyclovir | Purine Analog | C8 H11 N5 O3 |
| 5 | 2.508 | 340.1261 | 341.1332 | His Ala Asp | Amino Acid | C13 H19 |
| 6 | 2.522 | 335.1586 | 336.1648 | N2-Fructopyra-nosylarginine | Phenolic | C12 H24 N4 O7 |
| 7 | 2.601 | 266.083 | 267.0902 | PD 98059 | Flavonoid | C16 H13 N O3 |
| 8 | 2.623 | 264.0987 | 265.1059 | Agaritinal | Amino Acid derivative | C12 H15 N3 O4 |
| 9 | 2.649 | 219.0403 | 220.0479 | Quinazoline acetic acid (3(2H)-Quinazolineacetic acid, 1,4-dihydro-2,4-dioxo- | Alkaloid | C10 H8 N2 O4 |
| 10 | 2.683 | 195.0519 | 196.0592 | L-Gulonate | Carbohydrate | C6 H12 O7 |
| 11 | 2.686 | 165.0415 | 166.0488 | 1-Methylxanthine | Alkaloid | C6 H6 N4 O2 |
| 12 | 2.706 | 179.0573 | 180.0647 | Theobromine | Alkaloid | C7 H8 N4 O2 |
| 13 | 2.747 | 683.2275 | 342.1186 | Nigerose (Sakebiose) | Carbohydrate | C12 H22 O11 |
| 14 | 2.752 | 387.1165 | 388.1237 | Fructoselysine 6-phosphate | Glycated protein | C12 H25 N2 O10 P |
| 15 | 2.836 | 701.1932 | 666.2244 | Maltotetraose | Carbohydrate | C24 H42 O21 |
| 16 | 2.843 | 539.1408 | 504.1714 | Panose | Carbohydrate | C18 H32 O16 |
| 17 | 2.891 | 827.2702 | 828.2771 | Maltopentaose | Carbohydrate | C30 H52 O26 |
| 18 | 2.921 | 989.3229 | 990.3299 | Maltohexaose | Carbohydrate | C36 H62 O31 |
| 19 | 2.926 | 369.1042 | 370.1118 | 2′,3′,5′-triacetyl-5-Azacytidine | Pyrimidine nucleoside analogue | C14 H18 N4 O8 |
| 20 | 2.95 | 1,151.374 | 1,152.381s | Celloheptaose | Sugar | C42 H72 O36 |
| 21 | 2.966 | 149.0459 | 150.0532 | L-Lyxose | Aldehyde | C5 H10 O5 |
| 22 | 2.973 | 339.0972 | 304.1293 | 2′-Deoxymugineic acid | Carboxylic acid | C12 H20 N2 O7 |
| 23 | 2.978 | 366.1165 | 367.124 | Met Ser Met | Protein | C13 H25 N3 O5 S2 |
| 24 | 3.093 | 133.015 | 134.0225 | 3,3-Dimethyl-1,2-dithiolane | Dithiolanes | C5 H10 S2 |
| 25 | 3.259 | 290.0886 | 291.0959 | Sarmentosin epoxide | Glycoside | C11 H17 N O8 |
| 26 | 3.939 | 191.0202 | 192.0275 | Citric acid | Carboxylic acid | C6 H8 O7 |
| 27 | 4.026 | 128.0359 | 129.0431 | N-Acryloylglycine | Amino acid | C5 H7 N O3 |
| 28 | 4.164 | 243.0624 | 244.0698 | Uridine | Pyrimidine Nucleoside | C9 H12 N2 O6 |
| 29 | 4.403 | 130.0873 | 131.0945 | L-Leucine | Amino acid | C6 H13 N O2 |
| 30 | 4.534 | 180.0666 | 181.0738 | 3-Amino-3-(4-hydroxyphenyl) propanoate | Amino acid | C9 H11 N O3 |
| 31 | 4.58 | 292.1404 | 293.1476 | N-(1-Deoxy-1-fructosyl) leucine | Leucine & derivative | C12 H23 N O7 |
| 32 | 4.729 | 288.1242 | 289.1314 | Norcocaine | Alkaloid | C16 H19 N O4 |
| 33 | 4.828 | 103.0403 | 104.0475 | D (-)-β-hydroxy butyric acid | Carboxylic acid | C4 H8 O3 |
| 34 | 10.042 | 255.0519 | 256.0591 | Piscidic Acid | Phenolic | C11 H12 O7 |
| 35 | 10.536 | 153.0197 | 154.0269 | 3,4-Dihydroxybenzoic acid | Phenolic | C7 H6 O4 |
| 36 | 10.887 | 385.0568 | 386.0645 | Shoyuflavone A | Flavanoids | C19 H14 O9 |
| 37 | 11.228 | 175.0613 | 176.0685 | 3-propylmalic acid | Carboxylic acid | C7 H12 O5 |
| 38 | 11.325 | 239.0563 | 240.0636 | (1R,6R)-6-Hydroxy-2-succinylcyclohexa-2,4-diene-1-carboxylate | Gamma keto acid | C11 H12 O6 |
| 39 | 11.382 | 215.0827 | 216.09 | Desethyletomidate | Ethylester | C12 H12 N2 O2 |
| 40 | 11.573 | 183.03 | 184.0373 | 4-O-Methyl-gallate | Phenolic | C8 H8 O5 |
| 41 | 11.948 | 306.0619 | 307.0692 | Narciclasine | Alkaloid | C14 H13 N O7 |
| 42 | 11.949 | 352.067 | 353.0745 | 2,5-Diamino-6-hydroxy-4-(5′-phosphoribosylamino)-pyrimidine | N-glycosyl | C9 H16 N5 O8 P |
| 43 | 13.461 | 187.0977 | 188.105 | Nonic Acid | Pyruvic Acid | C9 H16 O4 |
| 44 | 17.614 | 293.1765 | 294.1838 | Gingerol | Phenolic | C17 H26 O4 |
RT: retention time.
FIGURE 1UHPLC - MS chromatogram of MEZ showing phytochemical profiling of extract.
Selected organ weights with standard deviation of treated and control group animals during acute and subacute toxicity Study.
| Dose (mg/kg) | Liver | Kidney | Pancreases | Lungs | Heart | Stomach | Brain | |
|---|---|---|---|---|---|---|---|---|
| Acute Toxicity |
| 1.56 ± 0.09 | 0.43 ± 0.06 | 0.12 ± 0.018 | 0.26 ± 0.0 4 | 0.14 ± 0.02 | 0.25 ± 0.02 | 0.39 ± 0.017 |
|
| 1.53 ± 0.05 | 0.41 ± 0.03 | 0.14 ± 0.03 | 0.24 ± 0.04 | 0.12 ± 0.01 | 0.24 ± 0.014 | 0.40 ± 0.02 | |
| Subacute Toxicity (Male) |
| 1.30 ± 0.03 | 0.44 ± 0.03 | 0.12 ± 0.01 | 0.27 ± 0.01 | 0.13 ± 0.003 | 0.23 ± 0.01 | 0.42 ± 0.02 |
|
| 1.15 ± 0.08 | 0.35 ± 0.03 | 0.11 ± 0.18 | 0.21 ± 0.01 | 0.13 ± 0.003 | 0.22 ± 0.02 | 0.40 ± 0.01 | |
|
| 1.58 ± 0.06 | 0.42 ± 0.04 | 0.15 ± 0.02 | 0.29 ± 0.02 | 0.14 ± 0.01 | 0.24 ± 0.01 | 0.37 ± 0.03 | |
|
| 1.57 ± 0.03 | 0.42 ± 0.03 | 0.14 ± 0.01 | 0.22 ± 0.01 | 0.12 ± 0.01 | 0.23 ± 0.012 | 0.39 ± 0.015 | |
| Subacute Toxicity (Female) |
| 1.46 ± 0.04 | 0.42 ± 0.03 | 0.13 ± 0.01 | 0.26 ± 0.01 | 0.13 ± 0.04 | 0.22 ± 0.01 | 0.4 ± 0.02 |
|
| 1.47 ± 0.08 | 0.37 ± 0.03 | 0.10 ± 0.018 | 0.22 ± 0.01 | 0.137 ± 0.008 | 0.23 ± 0.02 | 0.4 ± 0.017 | |
|
| 1.68 ± 0.09 | 0.42 ± 0.02 | 0.15 ± 0.01 | 0.28 ± 0.02 | 0.13 ± 0.01 | 0.24 ± 0.02 | 0.39 ± 0.03 | |
|
| 1.46 ± 0.08 | 0.34 ± 0.04 | 0.13 ± 0.02 | 0.25 ± 0.03 | 0.12 ± 0.009 | 0.24 ± 0.03 | 0.38 ± 0.03 |
FIGURE 2Average body weights ±SD of Male (A) and female (B) animals treated at different doses along with control during subacute toxicity study.
FIGURE 3Average body weights ±SD of treated animals at 2,000 mg/kg dose along with control group during acute toxicity study.
Complete blood count of treated and control group animals during acute oral toxicity study.
| Dose | Complete blood count (CBC) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WBC | LYM | MID | GRA | LYM | MID | GRA | RBC | HGB | MCV | HCT | MCH | MCHC | RDWsd | RDWcv | |
| 103/µL | 103/µL | 103/µL | 103/µL | % | % | % | 106/µL | g/dL | fL | % | pg | g/dL | fL | % | |
| 2000 mg/kg | 26.50 ± 2.27 | 4.58 ± 0.07 | 1.53 ± 0.26 | 0.74 ± 0.1 | 80.6 ± 0.20 | 18.9 ± 0.20 | 12.61 ± 0.24 | 8.59 ± 0.25 | 14.5 ± 0.5 | 52 ± 0.35 | 45.76 ± 0.29 | 17.83 ± 0.29 | 31.93 ± 0.51 | 27.20 ± 0.36 | 17.16 ± 0.31 |
| CONTROL | 7.19 ± 0.20 | 6.92 ± 0.09 | 0.66 ± 0.04 | 0.23 ± 0.07 | 90.21 ± 0.16 | 52.3 ± 0.18 | 2.32 ± 0.1 | 8.28 ± 0.49 | 13.37 ± 0.34 | 48.9 ± 0.75 | 41.08 ± 0.25 | 16.08 ± 0.66 | 32.80 ± 0.61 | 28.07 ± 0.21 | 18.97 ± 0.42 |
| PLT | MPV | PCT | PDWsd | PDWcv | PLC-R | PLC-C | |||||||||
| 103/µL | fL | % | fL | % | % | 103/µL | |||||||||
| 2000 mg/kg | 375.67 ± 6.51 | 7.13 ± 0.15 | 0.68 ± 0.03 | 31.31 ± 0.14 | 44.0 ± 0.75 | 22.3 3 ± 0.58 | 215 ± 4.58 | ||||||||
| CONTROL | 594.00 ± 3.61 | 7.26 ± 0.10 | 0.41 ± 0.02 | 8.41 ± 0.31 | 47.93 ± 0.31 | 23.90 ± 0.38 | 140.23 ± 0.21 | ||||||||
Complete blood count of treated and control group animals during subacute toxicity study.
| Dose (mg/kg) | Male | Female | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WBC’s | WBC | LYM | MID | GRA | LYM | MID | GRA | WBC | LYM | MID | GRA | LYM | MID | GRA |
| 103/µL | 103/µL | 103/µL | 103/µL | % | % | % | 103/µL | 103/µL | 103/µL | 103/µL | % | % | % | |
| 100 | 5.43 ± 0.15 | 3.9 ± 0.01 | 1.07 ± 0.12 | 0.623 ± 0.08 | 72.3 ± 0.20 | 17.3 ± 0.40 | 10.33 ± 0.15 | 5.40 ± | 3.90 ± | 1.00 ± | 0.60 ± | 72.10 ± | 17.70 ± | 10.20 ± |
| 200 | 5.503 ± 0.06 | 4.78 ± 0.02 | 0.58 ± 0.04 | 0.21 ± 0.1 | 85.46 ± 0.4 | 10.8 ± 0.46 | 3.343 ± 0.06 | 5.50 ± | 4.80 ± | 0.60 ± | 0.20 ± | 85.90 ± | 10.70 ± | 3.40 ± |
| 400 | 5.63 ± 0.32 | 2.55 ± 0.06 | 2.77 ± 0.08 | 0.31 ± 0.04 | 43.36 ± 1.30 | 50.5 ± 0.50 | 5.58 ± 0.080 | 5.90 ± | 2.61 ± | 2.70 ± | 0.31 ± | 43.80 ± | 50.50 ± | 5.65 ± |
| CONTROL | 6.18 ± 0.13 | 5.34 ± 0.06 | 0.6 ± 0.02 | 0.11 ± 0.02 | 88.16 ± 0.25 | 48.3 ± 0.1 | 2.09 ± 0.04 | 6.33 ± | 5.35 ± | 0.58 ± | 0.11 ± | 87.90 ± | 9.46 ± | 2.13 ± |
FIGURE 4Biochemical markers with ±SD in both male and female animals of treatment and control group during subacute study, LFTs (A,B), RFTs (C,D) and total lipid profile (E,F), respectively.
Biochemical marker analysis after treatment of 2000 mg/kg and control group during acute toxicity study.
| Biochemical marker | Unit | 2000 mg/kg | Control |
|---|---|---|---|
| ALT | U/L | 28.9 ± 2.15 | 14 ± 1.43 |
| AST | U/L | 100.5 ± 3.62 | 74 ± 2.7 |
| ALP | U/L | 119.5 ± 10.57 | 145 ± 6.69 |
| Uric Acid | mg/dL | 12.43 ± 0.19 | 8.13 ± 0.08 |
| Urea | mg/dL | 1.6 ± 0.36 | 7.7 ± 0.22 |
| Creatinine | mg/dL | 0.82 ± 0.05 | 0.46 ± 0.1 |
| Protein | g/dL | 15.4 ± 0.38 | 13.13 ± 0.20 |
| Bilirubin | mg/dL | 1.91 ± 0.22 | 2.24 ± 0.15 |
| Cholesterol | mg/dL | 44.73 ± 4.68 | 48.23 ± 3.42 |
| Triglycerides | mg/dL | 37.92 ± 1.73 | 35.36 ± 1.56 |
| HDL | mg/dL | 27.32 ± 3.72 | 30.22 ± 2.58 |
| LDL | mg/dL | 12.34 ± 0.78 | 15.94 ± 0.64 |
Effect of test doses of MEZ on clinical signs of behavioral and physical parameters in the acute oral toxicity study.
| Clinical parameter | Control | 2,000 mg/kg |
|---|---|---|
| Itching | - | - |
| Eye discharge | - | - |
| Nasal discharge | - | + |
| Skin lesion | - | - |
| Respiratory distress | - | - |
| Abnormal movement | - | - |
| Urination | Normal | Normal |
| Food intake | Normal | Normal |
| Water Intake | Normal | Normal |
No clinical sign (-), mild clinical sign present (+), Moderate to Severe sign present (++).